ClinicalTrials.gg
WithdrawnNCT02486848Updated Jan 24, 2017

Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil

An interventional study of 5% Topical Minoxidil Solution and 15% Topical Minoxidil Solution in Female Pattern Hair Loss and Androgenetic Alopecia, sponsored by Maja Kovacevic, MD. Withdrawn at 1 site in Italy. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-01-24.

Sponsored by Maja Kovacevic, MD · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing minoxidil in Alopecia — 10 open to participants now, 12 under way, 3 of them phase 3. Minoxidil · Alopecia.

Enrollment
29th of 31
0 · median 60
Started
2016
with 1 other
No phase
8 of 31
3 open now
Registered
10th of 31
by date

Among the 31 studies testing minoxidil in Alopecia, this one is the 29th largest by enrollment, is one of 2 that started in 2016, is one of 8 with no phase, and was the 10th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

10 of the 31 studies testing minoxidil in Alopecia are open now, in 5 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About minoxidil

Minoxidil: first FDA approval 1979 (LONITEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 55 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing minoxidil in Alopecia, or all of them as a file.
02

Study summary

5% topical minoxidil is the maximum dosage approved by the US FDA for the treatment of female pattern hair loss. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population is relatively low i.e., 30-40% re-grow hair.

The primary purpose of this study is to assess if a higher dosage of topical minoxidil dosage (15%) will increase the number of responders among female subjects that have been identified through IVD testing as non-responders to 5% topical minoxidil.

Read the detailed description

Approximately, 40% of women suffer from female pattern hair loss by the age of 55. Currently, there is only one drug approved by the US FDA for the treatment of female pattern hair loss (AGA) - topical minoxidil.

5% topical minoxidil is the maximum dosage approved by the US FDA for the treatment of female AGA. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population is relatively low i.e., 30-40% re-grow hair.

Minoxidil is a pro-drug. To elicit a clinical response, minoxidil must be converted to its active form minoxidil sulfate by a sulfotransferase enzyme found in hair follicles. The investigators have developed an in-vitro diagnostic test that correctly identifies, prior to initiating therapy, 95.9% of non-responders to 5% topical minoxidil. The diagnostic test analyzes the sulfotransferase enzymatic activity in hair follicles to determine if a sufficient amount of minoxidil will be converted to the active form required to induce hair growth. Subjects with low enzymatic activity experience little or no therapeutic benefit and a reduced frequency of adverse events.

Consequently, the investigators hypothesize that in subjects with low enzymatic activity (i.e., low minoxidil metabolizers) an increased minoxidil dosage will elicit a therapeutic response with little or no increase in the frequency of adverse events. It is thus the primary purpose of this study to assess if a higher dosage of topical minoxidil dosage (15%) will increase the number of responders among female subjects that have been identified through IVD testing as non-responders to 5% topical minoxidil.

03

Conditions studied

  • Female Pattern Hair Loss
  • Androgenetic Alopecia

Browse trials for

Keywords

  • Hairloss
  • Female Pattern Hair Loss
  • Androgenetic Alopecia
  • Minoxidil
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females in overall good health
  • Age: 18 to 55
  • Female pattern hair loss (Sinclair 2-4)
  • Willing to have a mini dot tattoo placed in the target area of the scalp
  • Willing to maintain the same hair style, color, shampoo and hair products use, and approximate hair length throughout the study
  • Able to give
  • Non-responder to 5% minoxidil as determined by the MX-IVD test i.e., low minoxidil metabolizer
  • Able to comply with the study requirements for 24 consecutive weeks
  • Willing to use an adequate method of (if applicable)
  • Negative urine pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Previous adverse event from topical minoxidil treatment
  • History of hypotension
  • Uncontrolled hypertension
  • Use of any hypertensive drugs
  • Pregnant, nursing, or planning a pregnancy during the study
  • Prior hair transplant
  • Uses wigs or hair weaves
  • Have used minoxidil (topical or oral) anytime during the past 6 months
  • Chronic scalp disorders that require medications
  • Uses medication known to cause hair thinning such as Coumadin and anti-depressants/anti-psychotics
  • Folliculitis
  • Scalp psoriasis
  • Seborrheic dermatitis
  • Inflammatory scalp conditions such as lichen planopilaris
  • Enrolled in any other medical study or has been enrolled in any medical study in the past 30 days
  • Responder to 5% minoxidil as determined by the MX-IVD test
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    5% Topical Minoxidil Solution

    5% Topical Minoxidil Solution

    Drug: 5% Topical Minoxidil Solution

  • Active comparator
    15% Topical Minoxidil Solution

    15% Topical Minoxidil Solution

    Drug: 15% Topical Minoxidil Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Target Area Hair Count

    Target Area Hair Count. Number of hairs measured in the target area by macrophotography

    Time frame: baseline to week 24

  2. Subjects Ratings

    Subjects Ratings

    Time frame: baseline to week 24

Secondary outcomes

  1. Target Area Hair Count

    Target Area Hair Count. Number of hairs measured in the target area by macrophotography.

    Time frame: baseline to week 12

  2. Expert Panel Global Photography Assessment

    Treatment efficacy evaluated by expert panel review of global photographs assessing hair regrowth

    Time frame: baseline to week 24

07

Study locations

1 site
  • Istituto Scienze Dermatologiche
    Florence, Tuscany, Italy
08

References and documents

Publications

  • Roberts J, Desai N, McCoy J, Goren A. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia. Dermatol Ther. 2014 Jul-Aug;27(4):252-4. doi: 10.1111/dth.12130. Epub 2014 Apr 28. PubMed 24773771 ↗
  • Goren A, Castano JA, McCoy J, Bermudez F, Lotti T. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatol Ther. 2014 May-Jun;27(3):171-3. doi: 10.1111/dth.12111. Epub 2013 Nov 27. PubMed 24283387 ↗
  • Buhl AE, Waldon DJ, Baker CA, Johnson GA. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol. 1990 Nov;95(5):553-7. doi: 10.1111/1523-1747.ep12504905. PubMed 2230218 ↗
  • Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004 Feb;150(2):186-94. doi: 10.1111/j.1365-2133.2004.05785.x. PubMed 14996087 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2015
First posted
Jul 1, 2015
Start
Jun 2016
Primary completionEst.
Dec 2016
CompletionEst.
Dec 2016
Last update
Jan 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02486848
Lead sponsor
Maja Kovacevic, MD
Responsible party
Maja Kovacevic, MD (Clinical Researcher, Applied Biology, Inc.) — Sponsor-investigator
First posted
Jul 1, 2015
Start date
Jun 2016
Primary completion
Dec 2016 (estimated)
Completion
Dec 2016 (estimated)
Last update
Jan 24, 2017

Study contacts

Maja Kovacevic, MD
principal investigator · University of Rome, Italy ("G. Marconi")

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Minoxidil

Start the discussion